Johnson & Johnson Reaches Agreement with Trump Administration to Reduce Medication Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Barron's
- Price Reduction Announcement: Johnson & Johnson will lower the prices of certain medications for U.S. consumers.
- Business Agreement Context: This move aligns with a broader trend of pharmaceutical companies forming agreements with the Trump administration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 119.750
Low
95.00
Averages
119.53
High
139.00
Current: 119.750
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoom Beats Earnings Estimates; Palantir and Kinsale Capital Show Strong Guidance
- Zoom's Strong Earnings: Zoom reported third-quarter revenue of $1.23 billion on November 24, surpassing the consensus estimate of $1.21 billion, indicating robust cash flow and market demand that could drive stock price growth.
- Palantir's Positive Outlook: Palantir's fourth-quarter results exceeded expectations, and the company provided first-quarter sales guidance above estimates, along with FY26 guidance that also surpassed analyst forecasts, highlighting its future growth potential.
- Kinsale Capital's Optimistic Forecast: Kinsale Capital shares rose 0.4% to close at $410.44 on Thursday, with analyst Hristian Getsov initiating coverage with an Overweight rating and a $490 price target, reflecting market confidence in its future performance.
- Merck's Drug Approval: Merck's ENFLONSIA received approval from Health Canada for preventing RSV lower respiratory tract disease in newborns and infants, with shares gaining 1.2% to close at $119.75, showcasing the company's ongoing innovation in the healthcare sector.
See More
Trump Administration Launches Drug Discount Website TrumpRx.gov
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
See More
MERCK & CO INC: GUGGENHEIM INCREASES TARGET PRICE FROM $122 TO $140
- Company Update: Merck & Co. has raised its price target for Gugenheim from $122 to $140.
- Market Impact: This adjustment reflects a positive outlook on the company's performance and potential growth.
See More
Website Reports That Numerous Popular Brand-Name Medications, Including Fertility and Weight Loss Drugs, Are Available on TrumpRx
- Drug Listings: Many commonly prescribed brand-name drugs, including those for fertility and weight loss, are listed on TrumpRx.
- TrumpRx Overview: The platform appears to focus on providing information about various medications, particularly those associated with specific health conditions.
See More
TRUMPRX.GOV WEBSITE GOES LIVE, REVEALS INFORMATION
Website Launch: A new website named "TRUMP RX GOV" has been launched, focusing on topics related to former President Donald Trump.
Content Features: The website showcases various content, likely including news, updates, and commentary on Trump's political activities and policies.
See More
TrumpRx Platform Set to Launch Today
- Direct-to-Consumer Platform: The Trump administration's upcoming TrumpRx platform, aimed at offering popular prescription drugs directly to consumers, is set to officially launch today at 7 PM ET, potentially transforming the drug sales model.
- Wide Industry Participation: At least 16 pharmaceutical companies, including Pfizer and AstraZeneca, have entered agreements with the Trump administration to sell drugs via TrumpRx, indicating broad industry support for the platform.
- Diverse Medication Offerings: TrumpRx will provide a variety of medications, including Novo Nordisk's weight-loss drug Wegovy, Eli Lilly's Zepbound, Amgen's cholesterol drug Repatha, and Merck's diabetes medication Januvia, catering to diverse consumer needs.
- Commitment to Price Transparency: The Trump administration aims to lower drug prices by eliminating intermediaries and selling directly to consumers, although it remains uncertain whether this model will genuinely result in cost reductions for cash-paying patients.
See More
Zoom Beats Earnings Estimates; Palantir and Kinsale Capital Show Strong Guidance
- Zoom's Strong Earnings: Zoom reported third-quarter revenue of $1.23 billion on November 24, surpassing the consensus estimate of $1.21 billion, indicating robust cash flow and market demand that could drive stock price growth.
- Palantir's Positive Outlook: Palantir's fourth-quarter results exceeded expectations, and the company provided first-quarter sales guidance above estimates, along with FY26 guidance that also surpassed analyst forecasts, highlighting its future growth potential.
- Kinsale Capital's Optimistic Forecast: Kinsale Capital shares rose 0.4% to close at $410.44 on Thursday, with analyst Hristian Getsov initiating coverage with an Overweight rating and a $490 price target, reflecting market confidence in its future performance.
- Merck's Drug Approval: Merck's ENFLONSIA received approval from Health Canada for preventing RSV lower respiratory tract disease in newborns and infants, with shares gaining 1.2% to close at $119.75, showcasing the company's ongoing innovation in the healthcare sector.
See More
Trump Administration Launches Drug Discount Website TrumpRx.gov
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
See More
MERCK & CO INC: GUGGENHEIM INCREASES TARGET PRICE FROM $122 TO $140
- Company Update: Merck & Co. has raised its price target for Gugenheim from $122 to $140.
- Market Impact: This adjustment reflects a positive outlook on the company's performance and potential growth.
See More
Website Reports That Numerous Popular Brand-Name Medications, Including Fertility and Weight Loss Drugs, Are Available on TrumpRx
- Drug Listings: Many commonly prescribed brand-name drugs, including those for fertility and weight loss, are listed on TrumpRx.
- TrumpRx Overview: The platform appears to focus on providing information about various medications, particularly those associated with specific health conditions.
See More
TRUMPRX.GOV WEBSITE GOES LIVE, REVEALS INFORMATION
Website Launch: A new website named "TRUMP RX GOV" has been launched, focusing on topics related to former President Donald Trump.
Content Features: The website showcases various content, likely including news, updates, and commentary on Trump's political activities and policies.
See More
TrumpRx Platform Set to Launch Today
- Direct-to-Consumer Platform: The Trump administration's upcoming TrumpRx platform, aimed at offering popular prescription drugs directly to consumers, is set to officially launch today at 7 PM ET, potentially transforming the drug sales model.
- Wide Industry Participation: At least 16 pharmaceutical companies, including Pfizer and AstraZeneca, have entered agreements with the Trump administration to sell drugs via TrumpRx, indicating broad industry support for the platform.
- Diverse Medication Offerings: TrumpRx will provide a variety of medications, including Novo Nordisk's weight-loss drug Wegovy, Eli Lilly's Zepbound, Amgen's cholesterol drug Repatha, and Merck's diabetes medication Januvia, catering to diverse consumer needs.
- Commitment to Price Transparency: The Trump administration aims to lower drug prices by eliminating intermediaries and selling directly to consumers, although it remains uncertain whether this model will genuinely result in cost reductions for cash-paying patients.
See More
